Phase I Study of SYD985 With Niraparib in Patients With Solid Tumors
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
SYD985.004 is a two-part phase I study with the antibody-drug conjugate SYD985 in combination
with niraparib aimed at evaluating safety, pharmacokinetics and efficacy in patients with
HER2-expressing locally advanced or metastatic solid tumours.